ImmPACT Bio racks up $111m Series B

ImmPACT Bio, a developer of transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, has raised $111 million in Series B financing.

ImmPACT Bio, a developer of transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, has raised $111 million in Series B financing. The investors include venBio Partners, Foresite Capital and Decheng Capital.

Source: Press Release